The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis

British Journal of Dermatology

Volumn 176, Issue 4, 2017, Pages 928-938

  Griffiths, C E M ^a   Thaci D ^b   Gerdes, S ^c   Arenberger, P ^d   Pulka, G ^e   Kingo, K ^f   Weglowska, J ^e   Hattebuhr, N ^g   Poetzl, J ^g   Woehling, H ^g   Wuerth, G ^g   Afonso, M ^g  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d CHARLES UNIVERSITY   (Czech Republic)

^e Grazyna Pulka Specjalistyczny Osrodek ‘ALL MED’ ul Sw Marka 31/IU ^*  (Poland)

^f TARTU UNIVERSITY HOSPITAL   (Estonia)

^g Sandoz Biopharmaceuticals   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOSIMILAR AGENT; ETANERCEPT; GAMMA GLUTAMYLTRANSFERASE; GP 2015; IMMUNOGLOBULIN A; UNCLASSIFIED DRUG; NEUTRALIZING ANTIBODY;

ADULT; ALCOHOL LIVER DISEASE; ARTHRALGIA; ARTICLE; BACKACHE; BRONCHITIS; CONTROLLED STUDY; COUGHING; DENTAL CARIES; DIABETES MELLITUS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELEVATED BLOOD PRESSURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; FEVER; FOLLICULITIS; GASTRITIS; HEADACHE; HERPES SIMPLEX; HUMAN; HYPERTENSION; HYPERURICEMIA; IMMUNOGENICITY; INJECTION SITE REACTION; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MELANOMA; MODERATE TO SEVERE CHRONIC PLAQUE TYPE PSORIASIS; MULTICENTER STUDY; NAUSEA; OROPHARYNX PAIN; PATIENT COMPLIANCE; PHARYNGITIS; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; RHINITIS; RHINOPHARYNGITIS; SCIATICA; SIDE EFFECT; SOMNOLENCE; SYSTEMIC THERAPY; THERAPEUTIC EQUIVALENCE; TONSILLITIS; TOOTH PAIN; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRAL RESPIRATORY TRACT INFECTION; VIRAL UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN; CHRONIC DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ADMINISTRATION; METABOLISM; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; ANTIBODIES, NEUTRALIZING; BIOSIMILAR PHARMACEUTICALS; CHRONIC DISEASE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG SUBSTITUTION; ETANERCEPT; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; PSORIASIS; TREATMENT OUTCOME;

EID: 85014009195     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.15152     Document Type: Article

References (32)

1. Bradley JR. TNF-mediated inflammatory disease. J Pathol 2008; 214:149–60.
2. Sedger LM, McDermott MF. TNF and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants – past, present and future. Cytokine Growth Factor Rev 2014; 25:453–72.
3. Leonardi CL, Powers JL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349:2014–22.
4. Tan JK, Aphale A, Malaviya R et al. Mechanisms of action of etanercept in psoriasis. J Investig Dermatol Symp Proc 2007; 12:38–45.
5. Blauvelt A, Cohen AD, Puig L et al. Biosimilars for psoriasis: preclinical analytical assessment to determine similarity. Br J Dermatol 2016; 174:282–6.
6. European Medicines Agency. Enbrel summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000262/WC500027361.pdf 2010 (last accessed 13 January 2017).
7. European Medicines Agency. Guideline on similar biological medicinal products. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf (last accessed 13 January 2017).
8. Weise M, Bielsky MC, De Smet K et al. Biosimilars – why terminology matters. Nat Biotechnol 2011; 29:690–3.
9. European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf (last accessed 13 January 2017).
10. ®). Expert Opin Biol Ther 2016; 16:1185–95.
11. von Richter O, Skerjanec A, Afonso M et al. GP2015, a proposed etanercept biosimilar: Pharmacokinetic similarity to its reference product and comparison of its autoinjector device with prefilled syringes. Br J Clin Pharmacol 2017; 83:732–41.
12. Langley RG, Feldman SR, Nyirady J et al. The 5-point Investigator's Global Assessment (IGA) scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat 2015; 26:23–31.
13. Papp KA, Tyring S, Lahfa M et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152:1304–12.
14. Brown H, Prescott R. Applied Mixed Models in Medicine, 2nd edn. Chichester: John Wiley & Sons Ltd, 2006.
15. Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005; 64 (Suppl. 2):ii65–8.
16. Tyring S, Gottlieb A, Papp K et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006; 367:29–35.
17. Sterry W, Ortonne JP, Kirkham B et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ 2010; 340:c147.
18. Strohal R, Puig L, Chouela E et al. The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial). J Dermatolog Treat 2013; 24:169–78.
19. Langley RG, Elewski BE, Lebwohl M et al. Secukinumab in plaque psoriasis – results of two phase 3 trials. N Engl J Med 2014; 371:326–38.
20. Thaçi D, Blauvelt A, Reich K et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol 2015; 73:400–9.
21. Emery P, Vencovsky J, Sylwestrzak A et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 2017; 76:51–7.
22. Mrowietz U, Leonardi CL, Girolomoni G et al. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol 2015; 73:27–36.
23. US Food and Drug Administration. Non-inferiority clinical trials to establish effectiveness. Guidance for industry. Available at: http://www.fda.gov/downloads/Drugs/Guidances/UCM202140.pdf (last accessed 13 January 2017).
24. Dranitsaris G, Dorward K, Hatzimichael E et al. Clinical trial design in biosimilar drug development. Invest New Drugs 2013; 31:479–87.
25. Tyring S, Gordon KB, Poulin Y et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007; 143:719–26.
26. Yoo DH, Oh C, Hong S et al. Analysis of clinical trials of biosimilar infliximab (CT-P13) and comparison against historical clinical studies with the infliximab reference medicinal product. Expert Rev Clin Immunol 2015; 11(Suppl. 1):S15–24.
27. Yoo DH, Hrycaj P, Miranda P et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013; 72:1613–20.
28. Choe JY, Prodanovic N, Niebrzydowski J et al. A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 2017; 76:58–64.
29. Zhang A, Tzeng JY, Chow SC. Statistical considerations in biosimilar assessment using biosimilarity index. J Bioequiv Availab 2013; 5:209–14.
30. Lai Z, La Noce A. Key design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an example. RMD Open 2016; 2:e000154.
31. Vincent FB, Morand EF, Murphy K et al. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 2013; 72:165–78.
32. de Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT et al. Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann Rheum Dis 2009; 68:531–5.